Alligator Bioscience AB
STO:ATORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alligator Bioscience AB
Other Current Assets
Alligator Bioscience AB
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alligator Bioscience AB
STO:ATORX
|
Other Current Assets
kr2.8m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other Current Assets
kr417.8m
|
CAGR 3-Years
192%
|
CAGR 5-Years
114%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other Current Assets
kr49.9m
|
CAGR 3-Years
67%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other Current Assets
kr74m
|
CAGR 3-Years
16%
|
CAGR 5-Years
46%
|
CAGR 10-Years
23%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other Current Assets
kr430m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
14%
|
|
|
BioArctic AB
STO:BIOA B
|
Other Current Assets
kr296.5m
|
CAGR 3-Years
168%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
Alligator Bioscience AB
Glance View
Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.
See Also
What is Alligator Bioscience AB's Other Current Assets?
Other Current Assets
2.8m
SEK
Based on the financial report for Dec 31, 2025, Alligator Bioscience AB's Other Current Assets amounts to 2.8m SEK.
What is Alligator Bioscience AB's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
6%
Over the last year, the Other Current Assets growth was 1%. The average annual Other Current Assets growth rates for Alligator Bioscience AB have been -30% over the past three years , 6% over the past five years .
